GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million

15.11.2023 - Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system ...

Related Keywords

Paris ,France General ,France ,Gensight Biologics ,European Medicines Agency ,Sofinnova Partners ,Sight Biologics ,Bridge Financing ,Sight Biologic ,Mitochondrial Targeting Sequence ,Leber Hereditary Optic Neuropathy ,Gensight Biologic ,Institut De La Vision ,Adeno Associated Virus ,Medicines Agency ,Process Performance Qualification ,Good Manufacturing Practice ,Marketing Authorisation Application ,Biologics License Application ,Gensight Biologics Stock ,